Encell EN001 Receives US FDA Orphan Drug Designation for Duchenne Muscular Dystrophy
Second ODD Designation Following Charcot-Marie-Tooth Disease
Stem Cell-Based Therapy Targeting Peripheral Nerves and Muscles
Encell, a company specializing in cell and gene therapies (CGT), announced on the 6th that its allogeneic umbilical cord-derived mesenchymal stem cell therapy candidate EN001 has additionally received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for Duchenne muscular dystrophy (DMD) as an indication.
This is the second achievement following its previous ODD approval for Charcot-Marie-Tooth disease (CMT). As a result, EN001 has been recognized for its therapeutic potential in rare diseases across two distinct pathological areas: peripheral neuropathy (CMT) and muscle degenerative disease (DMD). For drugs designated as ODD, the FDA supports the development and commercialization of innovative new medicines by offering various incentives, including seven years of market exclusivity after marketing approval, tax credits for clinical trial costs, and priority review.
DMD is a pediatric rare disease caused by defects in the dystrophin gene, which encodes a protein essential for maintaining muscle cells. Due to progressive muscle weakness, most patients lose their ability to walk after their teenage years, and currently there are very few treatment options that fundamentally slow the progression of the disease.
EN001 is a therapeutic agent based on allogeneic umbilical cord-derived mesenchymal stem cells (WJ-MSCs). It incorporates Encell's proprietary cell culture platform technology, ENCT, which suppresses cellular aging and enhances the secretion of factors related to anti-inflammation and tissue regeneration. It is considered to have therapeutic potential not only for the recovery of peripheral nerve damage, but also for controlling inflammation and preserving function in muscle tissue.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Encell CEO Jang Jongwook said, "This additional ODD designation is an objective validation that EN001 is a platform technology applicable not only to a single disease but across a broad range of intractable rare diseases with high unmet medical needs," adding, "We will focus our capabilities on accelerating clinical development and generating tangible global business outcomes going forward."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.